{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T06:14:12Z","timestamp":1769580852565,"version":"3.49.0"},"reference-count":34,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2012,4,1]],"date-time":"2012-04-01T00:00:00Z","timestamp":1333238400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Progress in Neuro-Psychopharmacology and Biological Psychiatry"],"published-print":{"date-parts":[[2012,4]]},"DOI":"10.1016\/j.pnpbp.2011.12.015","type":"journal-article","created":{"date-parts":[[2012,1,10]],"date-time":"2012-01-10T07:38:04Z","timestamp":1326181084000},"page":"128-131","source":"Crossref","is-referenced-by-count":10,"title":["Switching to aripiprazole in subjects with Pervasive Developmental Disorders showing tolerability issues with risperidone"],"prefix":"10.1016","volume":"37","author":[{"given":"Makoto","family":"Ishitobi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michio","family":"Hiratani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hirotaka","family":"Kosaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tetsuya","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomoyuki","family":"Mizuno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mizuki","family":"Asano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tetsuhito","family":"Murata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akemi","family":"Tomoda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuji","family":"Wada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.pnpbp.2011.12.015_bb0005","series-title":"Diagnostic and statistical manual of mental disorders","author":"American Psychiatric Association","year":"2000"},{"key":"10.1016\/j.pnpbp.2011.12.015_bb0010","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/j.biopsych.2006.02.032","article-title":"Effects of short- and long-term risperidone treatment on prolactin levels in children with autism","volume":"61","author":"Anderson","year":"2007","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.pnpbp.2011.12.015_bb0015","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1177\/026988110201600113","article-title":"A systematic review of the use of atypical antipsychotics in autism","volume":"16","author":"Barnard","year":"2002","journal-title":"J Psychopharmacol"},{"key":"10.1016\/j.pnpbp.2011.12.015_bb0020","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1017\/S1092852900019489","article-title":"Aripiprazole in the treatment of pediatric bipolar disorder: a systematic chart review","volume":"10","author":"Biederman","year":"2005","journal-title":"CNS Spectr"},{"key":"10.1016\/j.pnpbp.2011.12.015_bb0025","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1017\/S1092852900021519","article-title":"An open-label trial of aripiprazole monotherapy in children and adolescents with bipolar disorder","volume":"12","author":"Biederman","year":"2007","journal-title":"CNS Spectr"},{"key":"10.1016\/j.pnpbp.2011.12.015_bb0030","doi-asserted-by":"crossref","first-page":"723","DOI":"10.2147\/NDT.S1450","article-title":"Risperidone in the treatment of behavioral disorders associated with autism in children and adolescents","volume":"4","author":"Canitano","year":"2008","journal-title":"Neuropsychiatr Dis Treat"},{"key":"10.1016\/j.pnpbp.2011.12.015_bb0175","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1007\/s00213-002-1344-3","article-title":"Switching patients to aripiprazole from other antipsychotic agents: a multicenter randomized study","volume":"166","author":"Casey","year":"2003","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.pnpbp.2011.12.015_bb0040","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1016\/j.pnpbp.2010.08.012","article-title":"Differential add-on effects of aripiprazole in resolving hyperprolactinemia induced by risperidone in comparison to benzamide antipsychotics","volume":"34","author":"Chen","year":"2010","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"10.1016\/j.pnpbp.2011.12.015_bb0045","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1007\/BF02172092","article-title":"Domains of the Childhood Autism Rating Scale: relevance for diagnosis and treatment","volume":"24","author":"DiLalla","year":"1994","journal-title":"J Autism Dev Disord"},{"key":"10.1016\/j.pnpbp.2011.12.015_bb0180","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1097\/JCP.0b013e31817dd520","article-title":"Tolerability and pharmacokinetics of aripiprazole in children and adolescents with psychiatric disorders: an open-label, dose-escalation study","volume":"28","author":"Findling","year":"2008","journal-title":"J Clin Psychopharmacol"},{"key":"10.1016\/j.pnpbp.2011.12.015_bb0185","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1176\/appi.ajp.2008.07061035","article-title":"A multiple-center, randomized, double-blind, placebo-controlled study of oral aripiprazole for treatment of adolescents with schizophrenia","volume":"165","author":"Findling","year":"2008","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.pnpbp.2011.12.015_bb0060","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1177\/026988110401800308","article-title":"Mechanism of action of aripiprazole predicts clinical efficacy and a favourable side-effect profile","volume":"18","author":"Hirose","year":"2004","journal-title":"J Psychopharmacol"},{"key":"10.1016\/j.pnpbp.2011.12.015_bb0065","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1016\/j.pnpbp.2010.07.011","article-title":"Adjunctive treatment with low-dosage aripiprazole for blonanserin-induced hyperprolactinemia in a female patient with schizophrenia","volume":"34","author":"Ishitobi","year":"2010","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"10.1016\/j.pnpbp.2011.12.015_bb0070","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/S0014-2999(02)01532-7","article-title":"The antipsychotic aripiprazole is a potent, partial agonist at the human 5-HT1A receptor","volume":"441","author":"Jordan","year":"2002","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.pnpbp.2011.12.015_bb0075","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1177\/0883073810382143","article-title":"Risperidone use in autism spectrum disorders: a retrospective review of a clinic-referred patient population","volume":"26","author":"Lemmon","year":"2011","journal-title":"J Child Neurol"},{"key":"10.1016\/j.pnpbp.2011.12.015_bb0080","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1080\/10673220802075852","article-title":"Pharmacological treatment options for autism spectrum disorders in children and adolescents","volume":"16","author":"Leskovec","year":"2008","journal-title":"Harv Rev Psychiatry"},{"key":"10.1016\/j.pnpbp.2011.12.015_bb0085","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1002\/mrdd.20062","article-title":"Novel treatments for autistic spectrum disorders","volume":"11","author":"Levy","year":"2005","journal-title":"Ment Retard Dev Disabil Res Rev"},{"key":"10.1016\/j.pnpbp.2011.12.015_bb0090","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1007\/BF02172145","article-title":"Autism Diagnostic Interview-Revised: a revised version of a diagnostic interview for caregivers of individuals with possible pervasive developmental disorders","volume":"24","author":"Lord","year":"1994","journal-title":"J Autism Dev Disord"},{"key":"10.1016\/j.pnpbp.2011.12.015_bb0095","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1097\/CHI.0b013e3181b76658","article-title":"A placebo-controlled, fixed-dose study of aripiprazole in children and adolescents with irritability associated with autistic disorder","volume":"48","author":"Marcus","year":"2009","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"10.1016\/j.pnpbp.2011.12.015_bb0100","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1089\/cap.2009.0121","article-title":"Aripiprazole in the treatment of irritability in pediatric patients (aged 6\u201317 years) with autistic disorder: results from a 52-week, open-label study","volume":"21","author":"Marcus","year":"2011","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"10.1016\/j.pnpbp.2011.12.015_bb0105","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.4088\/JCP.v64n0909","article-title":"A 3-year naturalistic study of 53 preschool children with pervasive developmental disorders treated with risperidone","volume":"64","author":"Masi","year":"2003","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.pnpbp.2011.12.015_bb0110","doi-asserted-by":"crossref","first-page":"511","DOI":"10.2165\/00023210-200923060-00005","article-title":"Aripiprazole monotherapy in children and young adolescents with pervasive developmental disorders: a retrospective study","volume":"23","author":"Masi","year":"2009","journal-title":"CNS Drugs"},{"key":"10.1016\/j.pnpbp.2011.12.015_bb0115","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1176\/appi.ajp.162.6.1142","article-title":"Risperidone for the core symptom domains of autism: results from the study by the autism network of the research units on pediatric psychopharmacology","volume":"162","author":"McDougle","year":"2005","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.pnpbp.2011.12.015_bb0120","doi-asserted-by":"crossref","first-page":"e1312","DOI":"10.1542\/peds.2011-0427","article-title":"A systematic review of medical treatments for children with autism spectrum disorders","volume":"127","author":"McPheeters","year":"2011","journal-title":"Pediatrics"},{"key":"10.1016\/j.pnpbp.2011.12.015_bb0125","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1517\/14656566.8.11.1579","article-title":"The status of pharmacotherapy for autism spectrum disorders","volume":"8","author":"Myers","year":"2007","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.pnpbp.2011.12.015_bb0130","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1016\/j.pnpbp.2004.06.020","article-title":"Aripiprazole: a new atypical antipsychotic with a different pharmacological mechanism","volume":"28","author":"Naber","year":"2004","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"10.1016\/j.pnpbp.2011.12.015_bb0135","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1097\/00004583-199804000-00014","article-title":"An open trial of risperidone in young autistic children","volume":"37","author":"Nicolson","year":"1998","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"10.1016\/j.pnpbp.2011.12.015_bb0140","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1542\/peds.2008-3782","article-title":"Aripiprazole in the treatment of irritability in children and adolescents with autistic disorder","volume":"124","author":"Owen","year":"2009","journal-title":"Pediatrics"},{"key":"10.1016\/j.pnpbp.2011.12.015_bb0190","series-title":"Aripiprazole: (Abilify) U.S. Full Prescribing Information","author":"Prinseton","year":"2009"},{"key":"10.1016\/j.pnpbp.2011.12.015_bb0150","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1177\/08830738050200071301","article-title":"Aripiprazole in children and adolescents: clinical experience","volume":"20","author":"Rugino","year":"2005","journal-title":"J Child Neurol"},{"key":"10.1016\/j.pnpbp.2011.12.015_bb0155","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1542\/peds.2003-0264-F","article-title":"Risperidone in the treatment of disruptive behavioral symptoms in children with autistic and other pervasive developmental disorders","volume":"114","author":"Shea","year":"2004","journal-title":"Pediatrics"},{"key":"10.1016\/j.pnpbp.2011.12.015_bb0195","series-title":"Risperidone: (Risperdal) U.S. Full Prescribing Information","author":"Titusville","year":"2009"},{"key":"10.1016\/j.pnpbp.2011.12.015_bb0165","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.pedhc.2008.12.001","article-title":"Pharmacologic treatment for the core deficits and associated symptoms of autism in children","volume":"23","author":"West","year":"2009","journal-title":"J Pediatr Health Care"},{"key":"10.1016\/j.pnpbp.2011.12.015_bb0170","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1089\/cap.2000.10.79","article-title":"Long-term risperidone for pervasive developmental disorder: efficacy, tolerability, and discontinuation","volume":"10","author":"Zuddas","year":"2000","journal-title":"J Child Adolesc Psychopharmacol"}],"container-title":["Progress in Neuro-Psychopharmacology and Biological Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0278584612000024?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0278584612000024?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,6,22]],"date-time":"2019-06-22T08:29:11Z","timestamp":1561192151000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0278584612000024"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,4]]},"references-count":34,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2012,4]]}},"alternative-id":["S0278584612000024"],"URL":"https:\/\/doi.org\/10.1016\/j.pnpbp.2011.12.015","relation":{},"ISSN":["0278-5846"],"issn-type":[{"value":"0278-5846","type":"print"}],"subject":[],"published":{"date-parts":[[2012,4]]}}}